Azenta Life Sciences Partners with PRECEDE Foundation for Cancer Detection
Azenta, Inc. (NASDAQ: AZTA) has recently taken a significant step by forming a strategic partnership with the PRECEDE Foundation, an organization dedicated to the early detection and prevention of pancreatic cancer. This collaboration aims to enhance the capabilities of both entities in addressing a critical health challenge that affects thousands each year.
Understanding Pancreatic Cancer
Current Statistics and Challenges
Pancreatic cancer remains one of the deadliest forms of cancer, ranking as the third-leading cause of cancer-related deaths. Annually, over 66,500 individuals receive a pancreatic cancer diagnosis, yet fewer than 15,000 manage to survive. The unsettling fact is that the five-year survival rate is only 13%, compared to much higher rates for cancers such as prostate, breast, and colon. This discrepancy largely stems from the lack of effective early detection methods for pancreatic cancer.
The Role of the PRECEDE Foundation
The PRECEDE Foundation, or Pancreatic Cancer Early Detection Consortium, is a beacon of hope for individuals with hereditary risk factors for developing pancreatic cancer. The consortium's mission is ambitious yet vital: to raise the five-year survival rate from 13% to 50% over the next decade. With over 60 academic medical centers involved, PRECEDE has created the largest cohort of high-risk patients, integrating clinical data and biospecimen tracking to push the boundaries of early detection innovation.
The Impact of Early Detection
Expert Opinion
Kathi Shea, Chief Client Solutions Officer at Azenta, shared her insight on the critical nature of early detection, stating, "Early detection is the key to survival in pancreatic cancer. We are proud to support PRECEDE’s pioneering work by managing and safeguarding their critical samples in our biorepository. This ensures that researchers can focus on their vital work, which may ultimately lead to tools and strategies that save lives. Our partnership underscores Azenta's commitment to being a valuable resource in the field of clinical and diagnostic research."
Azenta's Expertise in Sample Management
Azenta’s well-established global expertise in sample management plays a crucial role in upholding the quality and continuity required for the PRECEDE Foundation’s mission. The partnership enables researchers to dedicate their full attention to discovery and innovation without the distractions of logistical challenges.
Future Directions
Annual Meeting and Continued Collaboration
The PRECEDE Foundation is set to host its Annual Meeting soon, gathering international experts to discuss advancements and collaborative strategies in pancreatic cancer detection. As the Foundation continues its mission, the partnership with Azenta will facilitate further progress in research and outreach efforts.
About PRECEDE Consortium
The PRECEDE Consortium consists of an international, multi-institutional group comprised of experts and industry partners striving to increase survival rates for pancreatic cancer patients. With the largest cohort of high-risk patients and cutting-edge technologies, PRECEDE aims to advance early detection capabilities significantly.
About PRECEDE Foundation
As the fundraising and infrastructure arm of the PRECEDE initiative, the Foundation focuses on increasing awareness and funding necessary to achieve its goals. Their unwavering commitment aims to improve patient outcomes through enhanced early detection methodologies.
About Azenta Life Sciences
Azenta, Inc. (NASDAQ: AZTA) stands as a leading provider of life science solutions globally. By enabling organizations to expedite their breakthroughs and therapies, Azenta plays a vital role in clinical research and drug development across the pharmaceutical and biotech industries. Their comprehensive cold-chain sample management solutions and multiomics services are designed to support the top institutions worldwide in their research endeavors.
Contact Information
For the PRECEDE Foundation
For media inquiries regarding the PRECEDE Foundation, please contact Jessica Forres at jessica@ekkopr.com.
For Azenta Life Sciences
For inquiries related to Azenta Life Sciences, please reach out to Yvonne Perron at ir@azenta.com.
Frequently Asked Questions
1. What is the focus of the partnership between Azenta and PRECEDE?
The partnership aims to enhance early detection and prevention efforts in pancreatic cancer, allowing researchers to focus on important discoveries.
2. Why is early detection important for pancreatic cancer?
Early detection significantly increases the chances of survival, helping to improve patient outcomes in what is currently a highly lethal disease.
3. How does PRECEDE plan to increase the pancreatic cancer survival rate?
They aim to raise the survival rate from 13% to 50% within the next decade by improving screening and prevention methods.
4. What role does Azenta play in this partnership?
Azenta provides secure biorepository services and logistical support for the storage and management of vital study samples.
5. How can I learn more about Azenta’s services?
For more information, visit Azenta's official website at www.azenta.com.
